A Houston company has seen a spike in sales in their on-demand fitness training sessions, and the startup is adding features to help users stay sane and healthy while stuck inside. Photo courtesy of Kanthaka

Last week, Sylvia Kampshoff saw a spike in her sales — something very uncommon for companies at this time, unless they are selling hand sanitizer, face masks, or toilet paper.

Kampshoff's company isn't providing toiletries though. Houston-based Kanthaka is an on-demand personal trainer tool for users to book one-on-one sessions with fitness experts at their own homes. With the city of Houston announcing that all bars and restaurants close to patrons, fitness studios followed suit. And that for Kanthaka meant a rise in sessions bought in Houston, Austin, Denver, Chicago, or any of the fifteen cities the app has launched in.

While gyms might be closing, "people feel pretty safe about having people come into their home," Kampshoff says, "and on the other hand we are wanting to give more jobs to trainers who have lost their jobs."

Kanthaka now has two people on boarding new fitness professionals on the app, and trainers who are out of work because their gym closed can get in touch with Kanthaka about the opportunity.

This spike in sales is coming mostly from younger users — particularly those in their 20s — but usually, Kanthaka has about a third of its users in the 60 and up age group — a population of people most at-risk from the COVID-19, or coronavirus. With this in mind, Kampshoff started looking into non face-to-face options for people who aren't comfortable with in-home instruction.

Next week, Kampshoff will launch digital sessions on Kanthaka. The sessions will still be one-on-one, but virtual. They won't be any cheaper, but will still provide that individual, undivided attention from a professional trainer. Additionally, Kanthaka will host free group fitness broadcasts online, and some will even factor in kids who are also stuck inside without many options for activities.

In just one week, Kampshoff had to pivot and tap a third-party streaming provider for the new service, something she has been able to do thanks to Sputnik ATX, an Austin-based accelerator Kampshoff is a part of.

"They were the first ones to say, 'Hey you should go virtual,'" Kampshoff says. "We started talking about it for the first time on Friday."

Ultimately, Kampshoff hopes this pivot will allow people access to personal training, as well as provide work for fitness professionals during the uncertain times of the coronavirus outbreak.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.